11 Best Pot Stocks to Buy According to Hedge Funds

Page 4 of 10

7. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

On February 25, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q4 revenue of $1.2 billion, exceeding consensus estimates of $1.17 billion and marking 10% year-over-year growth. According to Renee Gala, president and chief executive officer of Jazz Pharmaceuticals, 2025 was an exceptional year for the company. Management highlighted 2025 as its 21st consecutive year of top-line growth, underscoring operational execution and portfolio durability. It boasted a revenue of $1.2 billion for the fourth quarter of 2025, reflecting 10% year-over-year growth and the company’s highest revenue quarter to date.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) cited momentum heading into 2026, including the potential launch of zanidatamab in gastroesophageal adenocarcinoma, ongoing commercialization of Modeyso and Zepzelca, and continued strength from Epidiolex and Xywav in epilepsy and narcolepsy, respectively. Jazz projects FY2026 revenue of between $4.25 and $4.5 billion, compared to consensus expectations near $4.5 billion.

On January 29, TD Cowen raised its price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $220 from $205 and maintained a Buy rating ahead of Q4 results, reflecting updated modeling and pipeline visibility.

Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on oncology and neuroscience, with a differentiated rare disease portfolio. It is considered a “stealth” cannabis company due to its ownership of the cannabidiol (CBD) drug Epidiolex.

Page 4 of 10